Commonwealth of Pennsylvania Public School Empls Retrmt SYS Grows Position in Gilead Sciences, Inc. (GILD)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 74,569 shares of the biopharmaceutical company’s stock after acquiring an additional 3,997 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Gilead Sciences were worth $4,848,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Athena Capital Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $27,000. Capital Financial Planning LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $27,000. Creative Financial Designs Inc. ADV increased its stake in shares of Gilead Sciences by 55.9% in the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares during the period. Claybrook Capital LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $32,000. Finally, We Are One Seven LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $37,000. Hedge funds and other institutional investors own 78.79% of the company’s stock.

Several equities research analysts have commented on GILD shares. Oppenheimer set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, April 22nd. ValuEngine lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. Mizuho set a $88.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, March 22nd. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, February 7th. Finally, Wells Fargo & Co decreased their price objective on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a report on Tuesday, February 5th. Eight equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $80.57.

In related news, Director Richard James Whitley sold 9,534 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the sale, the director now directly owns 34,669 shares in the company, valued at $2,270,126.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director John Francis Cogan sold 2,700 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total transaction of $175,689.00. Following the sale, the director now owns 57,560 shares of the company’s stock, valued at $3,745,429.20. The disclosure for this sale can be found here. Insiders have sold 28,602 shares of company stock valued at $1,863,445 over the last 90 days. 0.20% of the stock is currently owned by insiders.

Gilead Sciences stock opened at $66.89 on Monday. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $85.28 billion, a PE ratio of 10.88, a P/E/G ratio of 0.81 and a beta of 1.14. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business’s revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm posted $1.48 earnings per share. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.6 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.77%. The ex-dividend date of this dividend is Thursday, June 13th. Gilead Sciences’s payout ratio is 40.98%.

ILLEGAL ACTIVITY NOTICE: “Commonwealth of Pennsylvania Public School Empls Retrmt SYS Grows Position in Gilead Sciences, Inc. (GILD)” was first reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.thestockobserver.com/2019/05/27/commonwealth-of-pennsylvania-public-school-empls-retrmt-sys-grows-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: How to interpret Moving Average Convergence Divergence (MACD)

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.